FHTX Strangle Strategy
FHTX (Foghorn Therapeutics Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma.
FHTX (Foghorn Therapeutics Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $247.8M, a beta of 2.89 versus the broader market, a 52-week range of 3.27-6.95, average daily share volume of 146K, a public-listing history dating back to 2020, approximately 112 full-time employees. These structural characteristics shape how FHTX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.89 indicates FHTX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on FHTX?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current FHTX snapshot
As of June 29, 2026, spot at $4.85, ATM IV 23.90%, IV rank 4.48%, expected move 6.85%. The strangle on FHTX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.
Why this strangle structure on FHTX specifically: FHTX IV at 23.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a FHTX strangle, with a market-implied 1-standard-deviation move of approximately 6.85% (roughly $0.33 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated FHTX expiries trade a higher absolute premium for lower per-day decay. Position sizing on FHTX should anchor to the underlying notional of $4.85 per share and to the trader's directional view on FHTX stock.
FHTX strangle setup
The FHTX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With FHTX near $4.85, the first option leg uses a $5.09 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed FHTX chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 FHTX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $5.09 | N/A |
| Buy 1 | Put | $4.61 | N/A |
FHTX strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
FHTX strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on FHTX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on FHTX
Strangles on FHTX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the FHTX chain.
FHTX thesis for this strangle
The market-implied 1-standard-deviation range for FHTX extends from approximately $4.52 on the downside to $5.18 on the upside. A FHTX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current FHTX IV rank near 4.48% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on FHTX at 23.90%. As a Healthcare name, FHTX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to FHTX-specific events.
FHTX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. FHTX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move FHTX alongside the broader basket even when FHTX-specific fundamentals are unchanged. Always rebuild the position from current FHTX chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on FHTX?
- A strangle on FHTX is the strangle strategy applied to FHTX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With FHTX stock trading near $4.85, the strikes shown on this page are snapped to the nearest listed FHTX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are FHTX strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the FHTX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 23.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a FHTX strangle?
- The breakeven for the FHTX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current FHTX market-implied 1-standard-deviation expected move is approximately 6.85%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on FHTX?
- Strangles on FHTX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the FHTX chain.
- How does current FHTX implied volatility affect this strangle?
- FHTX ATM IV is at 23.90% with IV rank near 4.48%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.